Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Ozan, Yazici"'
Autor:
Orhun Akdogan, Betul Ogut, Osman Sutcuoglu, Aysenur Sert, Fatih Gurler, Nalan Akyurek, Nuriye Ozdemir, Ahmet Ozet, Ozan Yazici
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Growth differentiation factor-15 (GDF-15), a member of the TGF-β superfamily, is overexpressed in various cancers and facilitates immune evasion by inhibiting T-cell activation. GDFATHER-TRIAL’s phase 2a results demonstrated pr
Externí odkaz:
https://doaj.org/article/db4a573e19b24f1c82b55dbc73a1b3e1
Autor:
Fatih Kus MD, Deniz Can Guven PhD, Hasan Cagri Yildirim PhD, Baran Akagunduz PhD, Serdar Karakaya PhD, Osman Sutcuoglu PhD, Elvin Chalabiyev MD, Arif Akyildiz MD, Baris Koksal MD, Yigit Berk Sahin MD, Ece Karaca MD, Oguz Alp Kavruk MD, Nefise Tugce Zor MD, Firat Sirvan MD, Ozan Yazici PhD, Suayib Yalcin PhD
Publikováno v:
Integrative Cancer Therapies, Vol 23 (2024)
Aims: This study aimed to assess the habits and knowledge of cancer patients regarding the use of herbal medicines and dietary supplements in cancer patients receiving immune checkpoint inhibitors (ICI). Methods: The data of 181 cancer patients who w
Externí odkaz:
https://doaj.org/article/171b5c2135e74f2db40143086b69d588
Autor:
OSMAN SÜTCÜOĞLU, ZEYNEP SEZGİ ERDAL, ORHUN AKDOĞAN, EMRAH ÇELTİKÇİ, NURİYE ÖZDEMİR, AHMET ÖZET, MURAT UÇAR, OZAN YAZICI
Publikováno v:
Turkish Journal of Medical Sciences. 53:420-431
Autor:
Osman SÜTCÜOĞLU, Mehmet Arda İNAN, Aytuğ ÜNER, Gözde SAVAŞ, Hüseyin BORA, Ahmet ÖZET, Nazan GÜNEL, Nalan AKYÜREK, Ozan YAZICI, Nuriye ÖZDEMİR
Publikováno v:
Journal of Oncological Sciences. 9:23-32
Autor:
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klümpen, Stephen L Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W Valle, Li Yu, Usha Malhotra, Abby B Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Immaculada Ales Diaz, Gustavo Alves, Sumitra Anand, Cagatay Arslan, Jamil Asselah, Eric Assenat, Francine Aubin, Li-Yuan Bai, Yuxian Bai, Susan Bates, Stephen Begbie, Irit Ben-Aharon, Nina Beri, Marie-Luise Berres, Jean-Frederic Blanc, Ivan Borbath, Robert Bordonaro, Giovanni Brandi, Adam Burgoyne, Kritiya Butthongkomvong, Ke Cao, Marcela Carballido, Marcos Camandaroba, Stephan Lam Chang, Jen-Shi Chen, Ming-Huang Chen, Xiaoming Chen, Ashley Cheng, Tai-Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joelle Collignon, Antonio Cubillo Gracian, Sarah Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith De Vos, Maria Diab, Jacob Easaw, Martin Eatock, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernandez, Richard Finn, Fabio Franke, Masayuki Furukawa, Olumide Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gumus, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoglu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Juneul Hwang, Mevlude Inanc, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jimenez Fonseca, Warren Joubert, Jitlada Juengsamarn, Diego Kaen, Masahi Kanai, Stefan Kasper-Virchow, Ghazaleh Kazemi, Fergal Kelleher, Robin Kelley, Jin Won Kim, Jong Gwang Kim, Ana Beatriz Kinupe Abrahao, Heinz Klumpen, Mark Kochenderfer, Fatih Kose, Ho Ching Lam, Choong-kun Lee, Hyun Woo Lee, Margaret Lee, Myung Ah Lee, Wai Man Sarah Lee, Samuel Le Sourd, Dongliang Li, Wei Li, Houjie Liang, Tingbo Liang, Chun Sen Lim, Brian Lingerfelt, Charles Lopez, John Low, Teresa Macarulla Mercade, David Malka, Yimin Mao, Gianluca Masi, Steven McCune, Ray McDermott, Elaine McWhirter, Guillermo Mendez, Michele Milella, Tomonori Mizutani, Camila Moniz, Luisa Morales, Andres Jesús Munoz Martin, Bruno Nervi, Nuttapong Ngamphaiboon, Sang Cheul Oh, Berna Oksuzoglu, Darryl Outlaw, Mustafa Ozguroglu, Ozgur Ozyilkan, Claudio Painemeal, Yueyin Pan, Chuang Peng, Caroline Petorin, Denis Pezet, Derek Power, Shukui Qin, Aflah Roohullah, Hyewon Ryu, Pamela Salman, Rita Sasidharan, Taroh Satho, Kornelius Schulze, Martin Scott-Brown, Ruben Segovia, Thomas Seufferlin, Salvatore Siena, Isabelle Sinapi, Cristina Smolenschi, Tianqiang Song, Aumkhae Sookprasert, Nopadol Soparattanapaisarn, Naureen Starling, Stacey Stein, Salomon Stemmer, Haichuan Su, Rie Sugimoto, Thatthan Suksombooncharoen, Vincent Tam, Ai Lian Tan, Chih Kiang Tan, Suebpong Tanasanvimon, Giuseppe Tonini, Giampaolo Tortora, Akihito Tsuji, Rodrigo Uribe, Marino Venerito, Helena Verdaguer Mata, Ana Paula Victorino, James Wade, Dirk Thomas Waldschmidt, Lu Wang, Wan Zamaniah Wan Isahk, Harpeet Wasan, Rui Weschenfelder, Chun Yin Wong, Yoke Fui Wong, Suayib Yalcin, Patricio Yanez Weber, Xuezhong Yang, Hisateru Yasui, Ozan Yazici, Chia-Jui Yen, Jieer Ying, Wenchang Yu, Haitao Zhao
Publikováno v:
The KEYNOTE-966 Investigators, Kelley, R K, Ueno, M, Yoo, C, Finn, R S, Furuse, J, Ren, Z, Yau, T, Klümpen, H-J, Chan, S L, Ozaka, M, Verslype, C, Bouattour, M, Park, J O, Barajas, O, Pelzer, U, Valle, J W, Yu, L, Malhotra, U, Siegel, A B, Edeline, J & Vogel, A 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet
The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩
KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet, 401(10391), 1853-1865. Elsevier Limited
The Lancet
The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩
KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet, 401(10391), 1853-1865. Elsevier Limited
Background: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e2bc96e0f72cde5bf243ad704e6b14
https://pure.manchester.ac.uk/ws/files/261634672/Pembrolizumab_in_combination_with_gemcitabine_and_cisplatin_compared_with_gemcitabine_and_cisplatin_alone_for_advanced_biliary...28Mar2023.docx
https://pure.manchester.ac.uk/ws/files/261634672/Pembrolizumab_in_combination_with_gemcitabine_and_cisplatin_compared_with_gemcitabine_and_cisplatin_alone_for_advanced_biliary...28Mar2023.docx
Autor:
Yakup ERGÜN, Gökhan UÇAR, Selin AKTÜRK ESEN, Murat BARDAKÇI, Ziya KALKAN, Zuhat URAKÇI, Erdoğan ŞEYRAN, Mutlu DOĞAN, Gökşen İnanç İMAMOĞLU, Ozan YAZICI, Seda KAHRAMAN, Yusuf AÇIKGÖZ, Doğan UNCU
Publikováno v:
Journal of Oncological Sciences. 8:100-106
Autor:
Aysegul İlhan, Fatih Gurler, Funda Yilmaz, Erdogan Seyran, Vural Bastug, Bugra Gorgulu, Emrah Eraslan, Özgen Ahmet Yıldırım, Ozan Yazici, Ömür Berna Çakmak Öksüzoğlu
Publikováno v:
Cureus.
Autor:
Kübra ERDOĞAN, Nisbet YILMAZ, Ahmet ERDOĞAN, Osman SÜTÇÜOĞLU, Ozan YAZICI, Nuriye YILDIRIM ÖZDEMİR
Publikováno v:
SDÜ Tıp Fakültesi Dergisi.
Objective: Colorectal cancers (CRCs) are among the most common cancers all over the world with a high mortality rate. Many prognostic factors have been identified for these cancers, one of which is the lymph node ratio (LNR). The purpose of this stud
Publikováno v:
JAMA Oncology. 9:570
Autor:
Ozan Yazici
Publikováno v:
Demiryolu Mühendisliği. :13-21
Dünyanın farklı bölgelerinde birçok kompozit travers teknolojisi geliştirilmiştir. Bu teknolojiler geleneksel traversler olarak nitelenen çelik travers, ahşap travers ve beton traverslere potansiyel bir alternatif olarak ortaya çıkmıştı